4-蝶啶胺 | 6973-01-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 中文名称: 4-蝶啶胺
• 英文名称: 4-aminopteridine
• 英文别名: pteridin-4-ylamine；Pteridin-4-ylamin；4-Amino-pteridin；4-Aminopteridin；4-Pteridinamine；pteridin-4-amine
• CAS: 6973-01-9
• 化学式: C₆H₅N₅
• mdl: MFCD01694507
• 分子量: 147.139
• InChiKey: VFATYAVSACUHHG-UHFFFAOYSA-N

物化性质

• 熔点：
  305°C
• 沸点：
  257.23°C (rough estimate)
• 密度：
  1.3913 (rough estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.5
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  77.6
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-蝶啶胺 在 sodium hydroxide 作用下， 生成 4-羟基蝶啶
  参考文献：
  名称：

  Albert et al., Journal of the Chemical Society, 1951, p. 474,478

  摘要：

  DOI：
• 作为产物：
  描述：

  喋啶 在 potassium permanganate 、 氨 作用下， 以49%的产率得到4-蝶啶胺
  参考文献：
  名称：

  Hara, Hiroshi; Plas, Henk C. van der, Journal of Heterocyclic Chemistry, 1982, vol. 19, p. 1527 - 1529

  摘要：

  DOI：

文献信息

• Vasculostatic agents and methods of use thereof
  申请人：Wrasidlo Wolfgang

  公开号：US20050282814A1

  公开（公告）日：2005-12-22

  Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as retinopathies or macular degeneration or other vitreoretinal diseases, inflammatory diseases, vascular leakage syndrome, edema, transplant rejection, adult/acute respiratory distress syndrome (ARDS), and the like.

  提供了用于治疗与血管稳态受损相关的疾病的组合物和方法。发明的方法和组合物可用于治疗各种疾病，包括中风、心肌梗死、癌症、缺血/再灌注损伤、类风湿性关节炎等自身免疫疾病、眼部疾病如视网膜病变或黄斑变性或其他玻璃体视网膜疾病、炎症性疾病、血管渗漏综合征、水肿、移植排斥反应、成人/急性呼吸窘迫综合征（ARDS）等。
• 4-Piperidinecarboxamide modulators of vanilloid VR1 receptor
  申请人：Calvo R. Raul

  公开号：US20060116368A1

  公开（公告）日：2006-06-01

  This invention is directed to vanilloid receptor VR1 ligands. More particularly, this invention relates to hetero isonipecotic amides that are potent modulators of VR1 which are useful for the treatment and prevention of disease conditions in mammals.

  这项发明涉及辣椒素受体VR1配体。更具体地说，这项发明涉及对VR1具有潜在调节作用的杂环异尼泊酸酰胺，这些化合物对于治疗和预防哺乳动物的疾病状况是有用的。
• [EN] TRICYCLIC BENZOPYRAN COMPOUND AS ANTI-ARRHYTHMIC AGENTS<br/>[FR] COMPOSE DE BENZOPYRANNE TRICYCLIQUE EN TANT QU'AGENTS ANTI-ARRYTHMIQUES
  申请人：NISSAN CHEMICAL IND LTD

  公开号：WO2005090357A1

  公开（公告）日：2005-09-29

  This invention relates to benzopyran derivatives of formula (I) or (II), or pharmaceutically acceptable salts thereof wherein R1 and R2 are independently of each other hydrogen atom, C1-6alkyl group or C6-14aryl group, R3 is hydrogen atom or C1-6alkylcarbonyloxy group, or together with R4 forms a bond, R4 is hydrogen atom, or together with R3 forms a bond, m is an integer of 0 to 4, n is an integer of 0 to 4, V is a single bond, CR7R8, NR9, O, S, SO or SO2, R5 is hydrogen atom or C1-6alkyl group, R6 is hydrogen atom, C1-6alkyl group, C3-8cycloalkyl group, C3-8cycloalkenyl group, amino group, C1-6alkylamino group, di-C1-6alkylamino group, C6-14arylamino group, C2-9heteroarylamino group, C6-14aryl group, C2-9heteroaryl group or C2-9heterocyclyl group, A is 5-, 6- or 7-member ring fused with benzene ring, as constituent atom of the ring, oxygen atom, nitrogen atom or sulfur atom may be contained in the number of 1 to 3 alone or in a combination thereof, the number of unsaturated bond in the ring is 1, 2 or 3 including an unsaturated bond of the benzene ring to be fused, carbon atoms constituting the ring may be carbonyl or thiocarbonyl. These compounds are useful as an anti-arrhythmic agent.

  本发明涉及公式（I）或（II）的苯并吡喁衍生物，或其药学上可接受的盐，其中R1和R2分别是氢原子、C1-6烷基或C6-14芳基，R3是氢原子或C1-6烷基羰氧基，或与R4一起形成键，R4是氢原子，或与R3一起形成键，m是0到4的整数，n是0到4的整数，V是单键，CR7R8，NR9，O，S，SO或SO2，R5是氢原子或C1-6烷基，R6是氢原子，C1-6烷基，C3-8环烷基，C3-8环烯基，氨基，C1-6烷基氨基，二C1-6烷基氨基，C6-14芳基氨基，C2-9杂芳基氨基，C6-14芳基，C2-9杂芳基或C2-9杂环烷基，A是与苯环融合的5、6或7成员环，作为环的组成原子，氧原子、氮原子或硫原子可以单独或组合地包含在其中，环中的不饱和键数为1、2或3，包括与苯环融合的不饱和键，构成环的碳原子可以是羰基或硫代羰基。这些化合物可用作抗心律失常药物。
• Kinase inhibitors and methods of use thereof
  申请人：Doukas John

  公开号：US20070259876A1

  公开（公告）日：2007-11-08

  Compositions and methods and are provided for treating disorders associated with compromised vasculostasis. Invention methods and compositions are useful for treating a variety of disorders including for example, stroke, myocardial infarction, cancer, ischemia/reperfusion injury, autoimmune diseases such as rheumatoid arthritis, eye diseases such as uveitis, retinopathies or macular degeneration, macular edema or other vitreoretinal diseases, inflammatory diseases such as autoimmune diseases, vascular leakage syndrome, edema, or diseases involving leukocyte activation, transplant rejection, respiratory diseases such as asthma, adult or acute respiratory distress syndrome (ARDS), chronic obstructive pulmonary disease, and the like.

  提供了用于治疗与血管稳态受损相关的疾病的组合物和方法。发明方法和组合物可用于治疗多种疾病，包括中风、心肌梗死、癌症、缺血/再灌注损伤、类风湿关节炎等自身免疫疾病、眼部疾病如葡萄膜炎、视网膜病变或黄斑变性、黄斑水肿或其他玻璃体视网膜疾病、自身免疫疾病、血管渗漏综合征、水肿或涉及白细胞活化的疾病、移植排斥反应、呼吸道疾病如哮喘、成人或急性呼吸窘迫综合征（ARDS）、慢性阻塞性肺疾病等。
• USE OF PTERIDINE DERIVATIVES FOR THE TREATMENT OF INCREASED INTRACRANIAL PRESSURE, SECONDARY ISCHEMIA, AND DISORDERS ASSOCIATED WITH AN INCREASED LEVEL OF CYTOTOXIC REACTIVE OXYGEN SPECIES
  申请人：VASOPHARM GMBH

  公开号：US20130131071A1

  公开（公告）日：2013-05-23

  The present invention relates to the use of pteridine derivatives for the treatment of increased intracranial pressure, secondary ischemia, and disorders associated with an increased level of cytotoxic reactive oxygen species.

  本发明涉及使用黄嘌呤衍生物治疗颅内压增高、继发性缺血以及与细胞毒性活性氧自由基水平升高相关的疾病。